Please provide your email address to receive an email when new articles are posted on . The FDA approved paltusotine for first-line treatment of patients with acromegaly who did not respond to or ...
A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...
The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 ...
Clearing the way for a U.S. regulatory bid in the second half of this year are positive top-line results from Pathfindr-2, the second of two successful phase III studies testing the efficacy and ...
Acromegaly, a disorder primarily resulting from excessive secretion of growth hormone (GH) by pituitary adenomas, presents unique challenges in the context of pregnancy. This condition not only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results